[Comparison of immunochemotherapy and chemotherapy of stage IV gastric carcinoma]

Gan No Rinsho. 1985 Nov;31(14):1805-9.
[Article in Japanese]

Abstract

Fifty-eight patients with stage IV gastric carcinoma were studied for the 24-month survival rate after receiving immunochemotherapy (Mitomycin-C + FT 207 + OK 432 + PSK, 29 cases) and chemotherapy Mitomycin-C + FT 207, 29 cases). There were no differences in the background factors influencing survival time between the two groups. The survival rate of the immunochemotherapy group was higher than, that of chemotherapy group throughout the observation period, in addition to statistical significance in some periods. The 50% survival rate was 10 months, in the chemotherapy group and 18 months in immunochemotherapy group. The difference in survival between the nonresected cases with immunochemotherapy and the resected cases with chemotherapy was smaller than that between nonresected cases and resected cases of the chemotherapy or immunochemotherapy group. These results suggested that possibility that immunochemotherapy prolonged the survival of patients with stage IV gastric carcinoma.

Publication types

  • Clinical Trial
  • Comparative Study
  • Controlled Clinical Trial

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Biological Products / administration & dosage*
  • Combined Modality Therapy
  • Female
  • Humans
  • Male
  • Middle Aged
  • Mitomycin
  • Mitomycins / administration & dosage
  • Picibanil / administration & dosage*
  • Proteoglycans / administration & dosage*
  • Random Allocation
  • Stomach Neoplasms / drug therapy*
  • Stomach Neoplasms / mortality
  • Stomach Neoplasms / surgery
  • Tegafur / administration & dosage

Substances

  • Biological Products
  • Mitomycins
  • Proteoglycans
  • Tegafur
  • Picibanil
  • polysaccharide-K
  • Mitomycin